A citation-based method for searching scientific literature

Roberto Costante, Azzurra Stefanucci, Simone Carradori, Ettore Novellino, Adriano Mollica. Expert Opin Ther Pat 2015
Times Cited: 12







List of co-cited articles
30 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
188
16

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
16

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
407
16

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
16

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
Julio Rosenstock, Nikolaus Marx, Steven E Kahn, Bernard Zinman, John J Kastelein, John M Lachin, Erich Bluhmki, Sanjay Patel, Odd-Erik Johansen, Hans-Jürgen Woerle. Diab Vasc Dis Res 2013
113
16


Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.
G McInnes, M Evans, S Del Prato, M Stumvoll, A Schweizer, V Lukashevich, Q Shao, W Kothny. Diabetes Obes Metab 2015
60
16

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
16

A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
Toshiyuki Hibuse, Norikazu Maeda, Ken Kishida, Takekazu Kimura, Tomoko Minami, Eriko Takeshita, Ayumu Hirata, Yasuhiko Nakagawa, Susumu Kashine, Akemi Oka,[...]. Cardiovasc Diabetol 2014
21
16

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Kazufumi Nakamura, Hiroki Oe, Hajime Kihara, Kenei Shimada, Shota Fukuda, Kyoko Watanabe, Tsutomu Takagi, Kei Yunoki, Toru Miyoshi, Kumiko Hirata,[...]. Cardiovasc Diabetol 2014
87
16


Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.
Per-Henrik Groop, Mark E Cooper, Vlado Perkovic, Angela Emser, Hans-Juergen Woerle, Maximilian von Eynatten. Diabetes Care 2013
196
16

Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management.
G Crepaldi, M Carruba, M Comaschi, S Del Prato, G Frajese, G Paolisso. J Endocrinol Invest 2007
35
16


Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events.
Julio Rosenstock, Nikolaus Marx, Dietmar Neubacher, Thomas Seck, Sanjay Patel, Hans-Juergen Woerle, Odd Erik Johansen. Cardiovasc Diabetol 2015
61
16

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.
George R Lankas, Barbara Leiting, Ranabir Sinha Roy, George J Eiermann, Maria G Beconi, Tesfaye Biftu, Chi-Chung Chan, Scott Edmondson, William P Feeney, Huaibing He,[...]. Diabetes 2005
394
16

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
Nayyar Iqbal, Artist Parker, Robert Frederich, Mark Donovan, Boaz Hirshberg. Cardiovasc Diabetol 2014
48
16

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Lawrence A Leiter, Hwee Teoh, Eugene Braunwald, Ofri Mosenzon, Avivit Cahn, K M Prasanna Kumar, Alena Smahelova, Boaz Hirshberg, Christina Stahre, Robert Frederich,[...]. Diabetes Care 2015
48
16

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
488
16

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays.
Laura Guasch, Maria José Ojeda, Noemí González-Abuín, Esther Sala, Adrià Cereto-Massagué, Miquel Mulero, Cristina Valls, Montserrat Pinent, Anna Ardévol, Santiago Garcia-Vallvé,[...]. PLoS One 2012
21
16

The history of Ephedra (ma-huang).
M R Lee. J R Coll Physicians Edinb 2011
56
16

DPP-IV inhibitors: Beyond glycaemic control?
Andrew J Kwok, Meghavi Mashar, Kaivan Khavandi, Ian Sabir. Trends Cardiovasc Med 2014
5
40

Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Yoshihiro Banno, Yasufumi Miyamoto, Mitsuru Sasaki, Satoru Oi, Tomoko Asakawa, Osamu Kataoka, Koji Takeuchi, Nobuhiro Suzuki, Koji Ikedo, Takuo Kosaka,[...]. Bioorg Med Chem 2011
26
16

A Review of Natural Stimulant and Non-stimulant Thermogenic Agents.
Sidney J Stohs, Vladimir Badmaev. Phytother Res 2016
47
16

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts.
Laura Guasch, Esther Sala, María José Ojeda, Cristina Valls, Cinta Bladé, Miquel Mulero, Mayte Blay, Anna Ardévol, Santiago Garcia-Vallvé, Gerard Pujadas. PLoS One 2012
12
16

Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
Qing Li, Muxing Zhou, Li Han, Qing Cao, Xinning Wang, LeiLei Zhao, Jinpei Zhou, Huibin Zhang. Chem Biol Drug Des 2015
8
25

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
Kenton L Longenecker, Kent D Stewart, David J Madar, Clarissa G Jakob, Elizabeth H Fry, Sherwin Wilk, Chun W Lin, Stephen J Ballaron, Michael A Stashko, Thomas H Lubben,[...]. Biochemistry 2006
33
16

Combinatorial peptide library screening for discovery of diverse α-glucosidase inhibitors using molecular dynamics simulations and binary QSAR models.
Adriano Mollica, Gokhan Zengin, Serdar Durdagi, Ramin Ekhteiari Salmas, Giorgia Macedonio, Azzurra Stefanucci, Marilisa Pia Dimmito, Ettore Novellino. J Biomol Struct Dyn 2019
28
16


The role of incretins in glucose homeostasis and diabetes treatment.
Wook Kim, Josephine M Egan. Pharmacol Rev 2008
478
16

Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
M A Luque, N González, L Márquez, A Acitores, A Redondo, M Morales, I Valverde, M L Villanueva-Peñacarrillo. J Endocrinol 2002
98
8

Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.
Adriana Castello Costa Girardi, Lívia Emy Fukuda, Luciana Venturini Rossoni, Gerhard Malnic, Nancy Amaral Rebouças. Am J Physiol Renal Physiol 2008
78
8

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.
M Elle Saine, Dena M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito,[...]. BMC Pharmacol Toxicol 2015
4
25




Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
A Ram Hong, Jeun Lee, Eu Jeong Ku, Yul Hwangbo, Kyoung Min Kim, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang, Soo Lim. Diabetes Res Clin Pract 2015
11
9


Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.
Goutam C Mistry, Arthur J Bergman, Wei Zheng, David Hreniuk, Miguel A Zinny, Keith M Gottesdiener, John A Wagner, Gary A Herman, Marcella Ruddy. Br J Clin Pharmacol 2008
29
8

Effects of combination therapy with vildagliptin and valsartan in a mouse model of type 2 diabetes.
Katsutoshi Miyagawa, Tatsuya Kondo, Rieko Goto, Rina Matsuyama, Kaoru Ono, Sayaka Kitano, Shuji Kawasaki, Motoyuki Igata, Junji Kawashima, Takeshi Matsumura,[...]. Cardiovasc Diabetol 2013
23
8


Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study.
Janet B McGill, Lance Sloan, Jennifer Newman, Sanjay Patel, Christophe Sauce, Maximilian von Eynatten, Hans-Juergen Woerle. Diabetes Care 2013
140
8



Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Nasib Ervinna, Tomoya Mita, Eisuke Yasunari, Kosuke Azuma, Rica Tanaka, Satoshi Fujimura, Dewi Sukmawati, Takashi Nomiyama, Akio Kanazawa, Ryuzo Kawamori,[...]. Endocrinology 2013
125
8


Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Stephanie Berthet, Pascale Olivier, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. BMC Clin Pharmacol 2011
9
11


Gliptins - do they increase cardiovascular risk or benefit?
Sheila A Doggrell, Simon B Dimmitt. Expert Opin Drug Saf 2014
10
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.